share_log
Breakings ·  Nov 26 01:31
Scholar Rock Holding Shares Jump 37.5% After Rival Biohaven's Rare Genetic Disorder Drug Fails Trial Goal
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment